Heparin in the prophylaxis and treatment of venous thromboembolism and other thrombotic diseases

Handbook of Experimental Pharmacology

Volumn 207, Issue , 2012, Pages 179-209

  Gresele, Paolo ^a   Busti, Chiara ^a   Paganelli, Gloria ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Acute Coronary Syndrome (ACS); Fondaparinux; Heparin induced thrombocytopenia (HIT); Low Molecular Weight heparin (LMWH); Pulmonary Embolism (PE); Superficial Vein Thrombosis (VVT); Unfractionated Heparin (UFH); Venous Thromboembolism (VTE)

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; DICLOFENAC; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTEINASE INHIBITOR; THROMBIN; THROMBOPLASTIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTICLE; BLEEDING; CESAREAN SECTION; CHILD CARE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPRESSION GARMENT; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); MOBILIZATION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ORTHOPEDIC SURGERY; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SEPSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; SUPERFICIAL VEIN THROMBOSIS; SURGICAL PATIENT; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; CHILD; FEMALE; PREGNANCY COMPLICATION; REVIEW;

ACUTE CORONARY SYNDROME; CHILD; FEMALE; HEPARIN; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; VENOUS THROMBOEMBOLISM;

EID: 84861872901     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-23056-1_9     Document Type: Article

References (44)

1. Agnelli G, Bergqvist D, Cohen AT et al (2005) Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92:1212-1220
2. American College of Chest Physicians (2008) Antithrombotic and thrombolytic therapy: The American College of Chest Physicians evidenced-based clinical practice guidelines 8th edition. Chest 133:67s-968s
3. Anderson DR, Ginsberg JS, Burrows R, Brill-Edwards P (1991) Subcutaneous heparin therapy during pregnancy: a need for concern at the time of delivery. Thromb Haemost 65:248250
4. Andrew M, Marzinotto V, Massicotte P et al (1994) Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 35:78-83
5. Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477-1488
6. Barrellier MT (1993) Superficial venous thromboses of the legs. Phlebologie 46:633-639
7. Brambilla S, Ruosi C, La Maida GA et al (2004) Prevention of venous thromboembolism in spinal surgery. Eur Spine J 13:1-8
8. Brandjes DPM, Heijboer H, Buller HR et al (1992) Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 327:1485-1489
9. Buller HR, Davidson BL, Decousus H et al (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695-1702
10. Buller HR, Davidson BL, Decousus H et al (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140:867-873
11. Cohen AT, Davidson BL, Gallus AS et al (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332:325-329
12. Cordell-Smith JA, Williams SC, Harper WM et al (2004) Lower limb arthroplasty complicated by deep venous thrombosis: prevalence and subjective outcome. J Bone Joint Surg Br 86:99-101
13. Ferguson JJ, Califf RM, Antman EM et al (2004) Enoxaparin vs. unfractionated heparin in highrisk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292:45-54
14. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group (1996) Lowmolecular- weight heparin during instability in coronary artery disease. Lancet 347:561-568
15. Gallus AS, Jackaman J, Tillett J et al (1986) Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 2:1293-1296
16. Geerts WH, Heit JA, Clagett GP et al (2001) Prevention of venous thromboembolism. Chest 119:132-175
17. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG (2004) Prevention of venous thromboembolism. Chest 126:338S-400S
18. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R (1989) Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med 149:2233-2236
19. Hirsh J, Anand SS, Halperin JL, Fuster V; American Heart Association. (2001) Guide to Anticoagulant Therapy: Heparin. A Statement for Healthcare Professionals From the American Heart Association. Circulation 103:2994-3018
20. Hull RD, Raskob GE, Rosenbloom D et al (1990) Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 322:1260-1264
21. Hull RD, Schellong SM, Tapson VF et al (2006) Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis 22:31-38
22. Kher A, Samama MM (2005) Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists. J Thromb Haemost 3:473-481
23. Koch A, Bouges S, Ziegler S et al (1997) Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous metaanalyses. Br J Surg 84:750-759
24. Lausen I, Jensen R, Jorgensen LN et al (1998) Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg 164:657-663
25. Leclerc JR, Gent M, Hirsh J et al (1998) The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: A multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Arch Intern Med 158:873-878
26. Lozano FS, Almazan A (2003) Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: A prospective study. Vasc Endovascular Surg 37:415-420
27. Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 162:1729-1735
28. Newall F, Barnes C, Ignjatovic V et al (2003) Heparin-induced thrombocytopenia in children. J Paediatr Child Health 39:289-292
29. Nicolaides A, Irving D, Pretzell M et al (1973) The risk of deep-vein thrombosis in surgical patients. Br J Surg 60:312
30. Oler A, Whooley MA, Oler J et al (1996a) Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis. JAMA 276:811-815
31. Oler A, Whooley MA, Oler J, Grady D (1996b) Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 276:811-815
32. Petersen JL, Mahaffey KW, Hasselblad V et al (2004) Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: A systematic overview. JAMA 292:89-96
33. Prandoni P, Samama MM (2008) Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. Br J Haematol 141:587-597
34. Prandoni P, Tormene D, Pesavento R, Vesalio Investigators Group (2005) High vs. low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: A double-blind, randomized trial. J Thromb Haemost 3:1152-1157
35. PRISM PLUS Study Investigators (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338:1488-1497
36. Quinlan DJ, McQuillan A, Eikelboom JW (2004) Low-molecular weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: A metaanalysis of randomized, controlled trials. Ann Intern Med 140:175-183
37. Raschke RA, Reilly BM, Guidry JR et al (1993) Heparin dosing review. Ann Intern Med 119:104-109
38. Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R (2001) Excretion of low molecularweight heparin in human milk. Br J Clin Pharmacol 52:708-710
39. Risch L, Fischer JE, Herklotz R, Huber AR (2004) Heparin-induced thrombocytopenia in paediatrics: Clinical characteristics, therapy and outcomes. Intensive Care Med 30:1615-1624
40. Samama MM, Cohen AT, Darmon JY et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341:793-800
41. Schmugge M, Risch L, Huber AR et al (2002) Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 109:E10
42. Tagalakis V, Kahn SR, Libman M, Blostein M (2002) The epidemiology of peripheral vein infusion thrombophlebitis: A critical review. Am J Med 113:146-151
43. The OASIS-6 Trial Group (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519-1530
44. The Superficial Thrombophlebitis Treated by Enoxaparin Study Group (2003) A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 163:1657-1663